Trefoil Factors Peptide-3 is Associated with Residual Invasive Breast Carcinoma Following Neoadjuvant Chemotherapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Feb 13

PMID 30744593

Citations 9

Authors

Suhail Al-Salam

Manjusha Sudhadevi

Aktham Awwad

Mohamed Al Bashir

Affiliations

Soon will be listed here.

Abstract

Background: Breast carcinoma is the commonest cancer among UAE population and the most common cancer among females. Examination of the 5' promoter regions of trefoil factor 3 (TFF3) gene has identified putative estrogen and progesterone receptor-DNA binding domains as direct response elements to estrogen and progesterone that are linked to breast functions or steroid regulation. The study was designed to determine the role of TFF3 in breast cancer chemoresistance with the aim of establishing TFF3 expression as a biomarker for drug resistance.

Methods: In total, 133 cases of breast carcinoma treated with neo-adjuvant therapy were collected. Tissue samples from pre-neoadjuvant therapy as well as tissues from post-neo-adjuvant therapy of those cases were collected and stained with immunohistochemistry for TFF3, Bcl2, BAX, cleaved caspase-3, AKT-1, NF kappa B and Ki-67.

Results: There was increased expression of TFF3 in residual invasive carcinoma cells. There was a significant correlation between the expression of TFF3 in breast carcinoma cells and response to neoadjuvant chemotherapy (p = 0.0165). There was significant co-expression of TFF3 with AKT1 (p = 0.0365), BCl2 (p = 0.0152), and NF Kappa-B (p = 0.0243) in breast carcinoma cases with residual carcinoma following neoadjuvant therapy which support the role of TFF3 in chemoresistance.

Conclusion: The expression of TFF3 is significantly associated with residual breast carcinoma following neoadjuvant chemotherapy suggesting its expression is associated with increased resistance to chemotherapy. This is supported by its co-expression with antiapoptotic proteins; BCl2, AKT1 and NF Kappa-B in residual breast carcinoma cells and very low proliferating index and apoptotic bodies in residual tumors.

Citing Articles

TFF3 facilitates dormancy of anti-estrogen treated ER+ mammary carcinoma.

Chen S, Zhang X, Basappa B, Zhu T, Pandey V, Lobie P Commun Med (Lond). 2025; 5(1):45.

PMID: 39984660 PMC: 11845601. DOI: 10.1038/s43856-024-00710-9.

MORE: a multi-omics data-driven hypergraph integration network for biomedical data classification and biomarker identification.

Wang Y, Wang Z, Yu X, Wang X, Song J, Yu D Brief Bioinform. 2024; 26(1).

PMID: 39692449 PMC: 11653202. DOI: 10.1093/bib/bbae658.

Breast Cancer in the Arabian Gulf Countries.

Al-Shamsi H, Abdelwahed N, Abyad A, Abu-Gheida I, Afrit M, Abu ElFuol T Cancers (Basel). 2023; 15(22).

PMID: 38001658 PMC: 10670541. DOI: 10.3390/cancers15225398.

TFF3 as a Diagnostic Biomarker in Kidney Transplant Patients.

Rogulska K, Wojciechowska-Koszko I, Krasnodebska-Szponder B, Kwiatkowski P, Roszkowska P, Dolegowska B Int J Mol Sci. 2023; 24(15).

PMID: 37569301 PMC: 10418491. DOI: 10.3390/ijms241511925.

Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.

Routh E, Van Swearingen A, Sambade M, Vensko S, McClure M, Woodcock M Front Oncol. 2022; 12:818693.

PMID: 35992833 PMC: 9387304. DOI: 10.3389/fonc.2022.818693.

References

Taupin D, Wu D, Jeon W, Devaney K, Wang T, Podolsky D . The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest. 1999; 103(9):R31-8. PMC: 408349. DOI: 10.1172/JCI3304. View

Taupin D, Kinoshita K, Podolsky D . Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci U S A. 2000; 97(2):799-804. PMC: 15411. DOI: 10.1073/pnas.97.2.799. View

Kinoshita K, Taupin D, Itoh H, Podolsky D . Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol. 2000; 20(13):4680-90. PMC: 85884. DOI: 10.1128/MCB.20.13.4680-4690.2000. View

Chen Y, Lu Y, De Plaen I, Wang L, Tan X . Transcription factor NF-kappaB signals antianoikic function of trefoil factor 3 on intestinal epithelial cells. Biochem Biophys Res Commun. 2000; 274(3):576-82. DOI: 10.1006/bbrc.2000.3176. View

Hoffmann W, Jagla W, Wiede A . Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol. 2001; 16(1):319-34. DOI: 10.14670/HH-16.319. View

Borthwick J, Charnock-Jones D, Tom B, Hull M, Teirney R, Phillips S . Determination of the transcript profile of human endometrium. Mol Hum Reprod. 2003; 9(1):19-33. DOI: 10.1093/molehr/gag004. View

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

Durual S, Blanchard C, Estienne M, Jacquier M, Perrot V, Laboisse C . Expression of human TFF3 in relation to growth of HT-29 cell subpopulations: involvement of PI3-K but not STAT6. Differentiation. 2005; 73(1):36-44. DOI: 10.1111/j.1432-0436.2005.07301006.x. View

Zhu Y, Tan X . TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}. Am J Physiol Cell Physiol. 2005; 289(5):C1085-93. PMC: 2527239. DOI: 10.1152/ajpcell.00185.2005. View

10.

Gonzalez-Angulo A, Morales-Vasquez F, Hortobagyi G . Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608:1-22. DOI: 10.1007/978-0-387-74039-3_1. View

11.

Ahmed A, Griffiths A, Tilby M, Westley B, May F . TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol. 2012; 180(3):904-916. DOI: 10.1016/j.ajpath.2011.11.022. View

12.

Casado E, Moreno Garcia V, Sanchez J, Gomez Del Pulgar M, Feliu J, Maurel J . Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target. Int J Radiat Oncol Biol Phys. 2012; 84(5):1151-8. DOI: 10.1016/j.ijrobp.2012.01.083. View

13.

Sun Z, Liu H, Yang Z, Shao D, Zhang W, Ren Y . Intestinal trefoil factor activates the PI3K/Akt signaling pathway to protect gastric mucosal epithelium from damage. Int J Oncol. 2014; 45(3):1123-32. DOI: 10.3892/ijo.2014.2527. View

14.

Howell A, Anderson A, Clarke R, Duffy S, Evans D, Garcia-Closas M . Risk determination and prevention of breast cancer. Breast Cancer Res. 2014; 16(5):446. PMC: 4303126. DOI: 10.1186/s13058-014-0446-2. View

15.

Hanisch C, Sharbati J, Kutz-Lohroff B, Huber O, Einspanier R, Sharbati S . TFF3-dependent resistance of human colorectal adenocarcinoma cells HT-29/B6 to apoptosis is mediated by miR-491-5p regulation of lncRNA PRINS. Cell Death Discov. 2017; 3:16106. PMC: 5279457. DOI: 10.1038/cddiscovery.2016.106. View

16.

You M, Chen Y, Chong Q, Wu M, Pandey V, Chen R . Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget. 2017; 8(24):39323-39344. PMC: 5503616. DOI: 10.18632/oncotarget.16950. View

17.

Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R, Izzotti A . Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res. 2017; 7(6):1350-1371. PMC: 5489783. View

18.

Ishibashi Y, Ohtsu H, Ikemura M, Kikuchi Y, Niwa T, Nishioka K . Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci Rep. 2017; 7(1):4846. PMC: 5501858. DOI: 10.1038/s41598-017-05129-y. View

19.

Wang H, Cai J, Du S, Guo Z, Xin B, Wang J . Fractalkine/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT/NF-κB cascade in pancreatic cancer cells. Cell Biochem Funct. 2017; 35(6):315-326. DOI: 10.1002/cbf.3278. View

20.

Elobaid Y, Aw T, Lim J, Hamid S, Grivna M . Breast cancer presentation delays among Arab and national women in the UAE: a qualitative study. SSM Popul Health. 2018; 2:155-163. PMC: 5757829. DOI: 10.1016/j.ssmph.2016.02.007. View